Literature DB >> 15478310

Target intervention against multiple-risk markers to reduce cardiovascular disease in patients with type 2 diabetes.

Peter Gaede1, Oluf Pedersen.   

Abstract

The risk of cardiovascular disease is markedly increased in patients with type 2 diabetes with a prevalence twice as high compared to the background population. With the recognition of multiple concomitant risk factors for both microvascular as well as cardiovascular disease in type 2 diabetic patients, treatment strategies have changed during recent years. This review focuses on the many recent drug trials that have set the course for an effective multifactorial treatment of the disease. Thus, the Steno-2 Study has shown that an intensified multifactorial intervention targeting several risk factors for cardiovascular disease is capable of reducing the risk for a combined endpoint of cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, coronary interventions, revascularisation to legs, and amputations by 50%.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15478310     DOI: 10.1080/07853890410033612

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  3 in total

Review 1.  Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.

Authors:  Matthias Meier; Michael Hummel
Journal:  Vasc Health Risk Manag       Date:  2009-11-02

2.  Incremental risk-factor reduction improves overall cardiovascular benefit: is it time to abandon the silos?

Authors:  Jan Basile; Mark Houston; Carlos Ferrario
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-10       Impact factor: 3.738

3.  Clustering of cardiovascular risk factors in semi-urban communities in south-western Nigeria.

Authors:  R Oluyombo; P O Akinwusi; M O Olamoyegun; O E Ayodele; M B Fawale; O O Okunola; T O Olanrewaju; A Akinsola
Journal:  Cardiovasc J Afr       Date:  2016-06-10       Impact factor: 1.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.